

SUPPLEMENTARY INFORMATION

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

Edwards Pradenas^{1,¶}, Benjamin Trinité^{1,¶}, Víctor Urrea¹, Silvia Marfil¹, Carlos Ávila-Nieto¹, María Luisa Rodríguez de la Concepción¹, Ferran Tarrés-Freixas¹, Silvia Pérez-Yanes^{1,2}, Carla Rovirosa¹, Erola Ainsua-Enrich¹, Jordi Rodon³, Júlia Vergara-Alert³, Joaquim Segalés^{4,5}, Victor Guallar^{6,7}, Alfonso Valencia^{6,7}, Nuria Izquierdo-Useros¹, Roger Paredes^{1,8}, Lourdes Mateu⁸, Anna Chamorro⁸, Marta Massanella¹, Jorge Carrillo¹, Bonaventura Clotet^{1,8,9} and Julià Blanco^{1,9,*}

¹IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916, Badalona, Catalonia, Spain

²Laboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Sección de Medicina, Facultad de Ciencias de la Salud, Universidad de La Laguna (ULL), La Laguna, 38071, Tenerife, Spain.

³IRTA Centre de Recerca en Sanitat Animal (CRESA, IRTA-UAB), Campus de la UAB, 08193, Bellaterra, Catalonia, Spain

⁴UAB, Centre de Recerca en Sanitat Animal (IRTA-UAB), Campus de la UAB, 08193, Bellaterra, Catalonia, Spain

⁵Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193, Bellaterra, Catalonia, Spain

⁶Barcelona Supercomputing Center, 08034, Barcelona, Catalonia, Spain

⁷Catalan Institution for Research and Advanced Studies (ICREA), 08010, Barcelona, Catalonia, Spain

⁸Infectious Diseases Department, Fight against AIDS Foundation (FLS), Germans Trias i Pujol Hospital, 08916, Badalona, Catalonia, Spain

⁹University of Vic–Central University of Catalonia (UVic-UCC), 08500, Vic, Catalonia, Spain

[¶]Equal contribution

*Corresponding author:

Julià Blanco, PhD

Senior Researcher

Institut de Recerca de la Sida. IrsiCaixa, IGTP, Hospital Germans Trias i Pujol
Ctra. de Canyet s/n. 2a Planta Maternal. 08916 Badalona. Barcelona

Email: jblanco@irsicaixa.es

Tel: +34 934 656 374

Fax: +34 934 653 968




Figure S1. Patient and sampling distribution across the follow-up period. Top panels show the time points for sample collection among mild/asymptomatic (**a**) and hospitalized (**b**) individuals. Bottom panels show the time points for samples of individuals with a single measurement: **c**, mild/asymptomatic; **d**, hospitalized. Time count starts on the day of symptom onset, except for asymptomatic individuals, for whom the serological diagnosis was considered. The areas define the periods considered for the longitudinal analysis: days 0-30 (white), 30-80 (dark grey) and after 80 days (light grey).




Figure S2. Antibody titers at the end of the follow-up period. Antibody titers of the last measure for IgG against the receptor binding domain (RBD) (a), S2 (b), and nucleoprotein (NP) (c) on a subset of individuals with largest follow-up ($n=14$ for mild/asymptomatic and $n=14$ for hospitalized). Panel d shows the neutralizing activity of the same subset of individuals at the end of the follow-up period. Boxes show the median and the interquartile range, and bars the 10th and 90th percentiles. Severity groups (i.e., mild/asymptomatic and hospitalized) were compared using the Mann-Whitney test.